Figure 5.

Coadministration of CDKI-73 and olaparib demonstrates a strong therapeutic effect on ovarian cancer cells in vivo. Tumor-bearing nude mice were orally administered vehicle control (Ctrl), CDKI-73 (25 mg/kg), olaparib (50 mg/kg), or the combination of the two drugs daily for three weeks (n = 6). The coadministration of CDKI-73 and olaparib remarkably suppressed tumor growth. A. Images of harvested tumors from each treatment group. B. Tumor growth curves measured during treatment. C. Box and whiskers plot of tumor weight at sacrifice (minimum to maximum, the line represents the mean). *P < 0.05; **P < 0.01. D. Tumor volume changes (from the start to the end of treatment) in each treatment group are shown in a waterfall plot. E. Mouse weight was measured every 5 days during treatments. F. Representative IHC images of Ki67 and BRCA1 in formalin-fixed paraffin-embedded tumors. Scale bar, 200 μm.